Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohort.
Fiche publication
Date publication
janvier 2023
Journal
Breast cancer (Tokyo, Japan)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr EYMARD Jean-Christophe, Dr DESMOULINS Isabelle, Dr EBERST Lauriane
Tous les auteurs :
Collet L, Eberst L, Ludovic G, Debled M, Hrab L, Mouret-Reynier MA, Desmoulins I, Goncalves A, Campone M, Ferrero JM, Brain E, Uwer L, Eymard JC, Dieras V, Simon G, Leheurteur M, Dalenc F, Vanlemmens L, Darlix A, Arnedos M, Bachelot T
Lien Pubmed
Résumé
More than 10% of HER2-positive metastatic breast cancer (mBC) will develop Central Nervous System (CNS) metastases as first and isolated site of relapse on trastuzumab and pertuzumab first-line therapy. However, few clinical data are available to guide the best strategy in this setting.
Mots clés
Brain metastases, Breast neoplasms, Pertuzumab, Trastuzumab, Tyrosine kinase-type cell surface receptor HER2
Référence
Breast Cancer. 2023 01 11;: